Biolegend, 100336, Brilliant Violet 421™ anti-mouse CD3ε Antibody, 500microl

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.
500microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Armenian Hamster
Immunogen: H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The immunoglobulin was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality testedICC - Verified
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunocytochemistry using the µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block) Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ) Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB) Payer E, et al. 1991. J. Immunol. 146:2536. (IF) Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD) Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ) Henrickson M, et al. 1995. Transplantation 60:828. (Deplete) Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete) Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete) Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block) Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ) Ko SY, et al. 2005. J. Immunol. 175:3309. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F) Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F) Wang W, et al. 2007. J. Immunol. 178:4885. (Activ) Xiao S, et al. 2007. J. Exp. Med. 204:1691. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Kenna TJ, et al. 2008. Blood 111:2091. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed Schulteis RD, et al. 2008. Blood 295:G273. PubMed Qi Q, et al. 2009. Blood 114:564. PubMed Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed Yan J, et al. 2014. Vaccine. 32:2833. PubMed Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations: Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed Játiva S, et al. 2022. Biomed Pharmacother. 153:113415. PubMed Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed Chan L, et al. 2022. Cells. 12: . PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed Kuang Z, et al. 2020. Antib Ther. 3:227. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Li H, et al. 2021. Nat Commun. 12:2773. PubMed Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed Formaglio P, et al. 2021. Immunity. 54:2724. PubMed Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Lee C, et al. 2015. Nat Commun. 6: 8477. PubMed van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed Qi F, et al. 2019. Front Microbiol. 2.140277778. PubMed Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed Kiyohara H, et al. 2018. Cell Mol Gastroenterol Hepatol. 7:135. PubMed Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Kumar D, et al. 2018. Cancer Prev Res (Phila). 0.895138889. PubMed Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed Teng F, et al. 2021. Cell Rep. 37:110051. PubMed McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed Goc J, et al. 2021. Cell. 184:5015. PubMed
RRID: AB_10898314 (BioLegend Cat. No. 100335) AB_2562556 (BioLegend Cat. No. 100341) AB_11203705 (BioLegend Cat. No. 100336)
Structure: Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function: TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor: Peptide antigen/MHC-complex
Cell Type: NKT cells, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules, TCRs
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.
Gene ID: 12501
UniProt: View information about CD3epsilon on UniProt.org
Clone: 145-2C11
Regulatory Status: RUO
Other Names: CD3ε, T3, CD3
Isotype: Armenian Hamster IgG
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.